Gene Therapy Shows Promise Against Blood-Clotting Disease - NBC 6 South Florida
National & International News
The day’s top national and international news

Gene Therapy Shows Promise Against Blood-Clotting Disease

"The hope is that this would be a one-time treatment"

    processing...

    NEWSLETTERS

    Gene Therapy Shows Promise Against Blood-Clotting Disease
    AP/Courtesy Jay Konduros
    This Saturday, Dec. 2, 2017 photo provided by Jay Konduros, left, shows him and his brother, Bill, at Jay's home in Cambridge, Ontario, Canada. The brothers, who have hemophilia, were involved in a gene therapy study for their condition. Before the treatment, "Even something as innocuous as reaching over your head to get something out of a closet, or reaching down to tie a shoe" could trigger trouble, Bill said.

    sGene therapy has freed 10 men from nearly all symptoms of hemophilia for a year so far, in a study that fuels hopes that a one-time treatment can give long-lasting help and perhaps even cure the blood disease.

    Hemophilia almost always strikes males and is caused by lack of a gene that makes a protein needed for blood to clot. Small cuts or bruises can be life-threatening, and many people need treatments once or more a week to prevent serious bleeding.

    The therapy supplies the missing gene, using a virus that's been modified so it won't cause illness but ferries the DNA instructions to liver cells, which use them to make the clotting factor. The treatment is given through an IV.

    In a study published Wednesday by the New England Journal of Medicine, all 10 men given the therapy now make clotting factor in the normal range. Bleeding episodes were reduced from about one a month before gene therapy to less than one a year. Nine of the 10 no longer need clotting factor treatments, and the 10th needs far fewer of them. There were no serious side effects.

    Avalanche Buries Unknown Number of People in NM

    [NATL] Avalanche Buries Unknown Number of People in NM

    Ski Patrol and first responders are working to rescue an unknown number of skiers buried in an avalanche at Taos Ski Resort in New Mexico

    (Published Thursday, Jan. 17, 2019)

    Follow-up is still short — a year on average. Some cells with the new gene might not pass it on as they divide, so the benefits may wane over time, but they've lasted eight years in other tests in people and up to 12 years so far in dogs.

    "The hope is that this would be a one-time treatment" to fix the problem, said the study leader, Dr. Lindsey George of Children's Hospital of Philadelphia.

    Spark Therapeutics, the Philadelphia-based company that makes the treatment, and Pfizer, which now is working with Spark on it, paid for the study, and some of the study leaders work for or have stock in Spark.

    Dr. Matthew Porteus of Stanford University, who wrote a commentary in the journal, called the results "striking" and said, "I think we're definitely on the road" to a cure.

    It feels like one to Canadians Jay and Bill Konduras, brothers who live an hour's drive outside Toronto who were in the study.

    "It's pretty magical," said Jay Konduras, 53, who runs a bakery and was treated in June 2016.

    Iowa Man Gets "Jackpot Treatment" for $1 Lotto Ticket Win

    [NATL] Iowa Man Gets "Jackpot Treatment" for $1 Lotto Ticket Win

    An Iowa man got the "Jackpot treatment" after winning $1 off a scratch-off lotto ticket. Tyler Heep decided to cash in the winning ticket at the Iowa Lottery Headquarters and was presented with a big check for his win. Heep spent his winnings on a gallon of gas.

    (Published Thursday, Jan. 17, 2019)

    "Life-changing," said Bill Konduras, 58, a machinist treated in March.

    Before, even small amounts of exertion would cause tiny muscle tears and bleeding problems requiring clotting factor treatment.

    "Even something as innocuous as reaching over your head to get something out of a closet, or reaching down to tie a shoe" could trigger trouble, Bill Konduras said.

    Six years ago, he nearly lost his leg after a motorcycle crash tore open an artery; he spent nearly a month in the hospital. Since the gene therapy, neither brother has needed clotting factor treatment.

    The therapy is still experimental and its eventual cost is unknown, but clotting factor treatment costs about $200,000 per patient per year, Porteus said.

    Another gene therapy, from BioMarin Pharmaceutical for a different form of hemophilia, also showed promise in a different study. Thirteen patients have been treated and have had a big drop in bleeding episodes and clotting factor treatments, study leaders report. One-year results will be given at an American Society of Hematology conference that starts Saturday.

    ICE Detains Marine Veteran

    [NATL] ICE Detains Marine Veteran, Says No Investigation

    Family members are furious that a U.S. citizen and military veteran ended up in an immigration detention center facing the threat of deportation. Jilmar Ramos-Gomez was born and raised in Grand Rapids. His mother says he served a tour in Afghanistan while in the U.S. Marine Corps.

    (Published Thursday, Jan. 17, 2019)

    Other companies are working on hemophilia treatments; Sangamo Therapeutics is testing traditional gene therapy and gene editing approaches.